Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: Need for assay-specific decision limits and metabolite-specific assays

Annals of Clinical Biochemistry

Volumn 43, Issue 1, 2006, Pages 23-30

  Glendenning, P ^a   Taranto, M ^a   Noble, J M ^a   Musk, A A ^a   Hammond, C ^a   Goldswain, P R ^a   Fraser, W D ^b   Vasikaran, S D ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYERGOCALCIFEROL; CALCIFEDIOL; ERGOCALCIFEROL;

ANALYTIC METHOD; ARTICLE; ASSAY; BINDING ASSAY; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIP FRACTURE; HUMAN; INTERMETHOD COMPARISON; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; MEASUREMENT; METABOLITE; PRIORITY JOURNAL; PROTEIN BINDING; RADIOIMMUNOASSAY; REGRESSION ANALYSIS; SAMPLE; STATISTICAL SIGNIFICANCE;

25-HYDROXYVITAMIN D 2; CALCIFEDIOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HIP FRACTURES; HUMANS; SENSITIVITY AND SPECIFICITY;

EID: 30844433957     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/000456306775141650     Document Type: Article

References (31)

1. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001; 22: 477-501
2. Souberbielle JC, Cormier C, Kindermans C, et al. Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 2001; 86: 3086-90
3. Souberbielle JC, Lawson-Body E, Hammadi B, Sarfati E, Kahan A, Cormier C. The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J Clin Endocrinol Metab 2003; 88: 3501-4
4. 3 and calcium to prevent hip fractures in the elderly women. New Engl J Med 1992; 327: 1637-42
5. Bischoff HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003; 18: 343-51
6. Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab 2003; 88: 185-91
7. Lips P, Chapuy MC, Dawson-Hughes B, Pols HA, Holick MF. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporosis Int 1999; 9: 394-7
8. Carter GD, Carter R, Jones J, Berry J. How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem 2004; 50: 2195-7. (Epub 2004 Sep 2116)
9. Heaney RP. Vitamin D: how much do we need and how much is too much? Osteoporosis Int 2000; 11: 553-5
10. Vieth R. Problems with direct 25-hydroxyvitamin D assays, and the target amount of vitamin D nutrition desirable for patients with osteoporosis. Osteoporosis Int 2000; 11: 635-6
11. Carter GD, Carter CR, Gunter E, et al. Measurement of Vitamin D metabolites: an international perspective on methodology and clinical interpretation. J Steroid Biochem Mol Biol 2004; 89-90: 467-71
12. 3 in human plasma by liquid chromatography-tandem mass spectrometry employing derivatization with a Cookson-type reagent. Biol Pharm Bull 2001; 24: 738-43
13. 3 by liquid chromatography-tandem mass spectrometry. Clin Chem 2004; 50: 1415-7
14. Noble JM, McGuiness M, Glendenning P. Low rate of compliance with ergocalciferol therapy in vitamin-D-deficient patients with hip fracture. Med J Australia 2002; 177: 280
15. 3 does not affect 1,25-dihydroxy vitamin D. Ann Clin Biochem 1994; 31: 31-4
16. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-10
17. Stenman UH. Immunoassay standardization: is it possible, who is responsible, who is capable? Clin Chem 2001; 47: 815-20
18. Glendenning P. Issues of standardization and assay-specific clinical decision limits for the measurement of 25-hydroxyvitamin D. Am J Clin Nutr 2003; 77: 522-3
19. Glendenning P, Noble JM, Taranto M, et al. Issues of methodology, standardization and metabolite recognition for 25-hydroxyvitamin D when comparing the DiaSorin radioimmunoassay and the Nichols Advantage automated chemiluminescence protein-binding assay in hip fracture cases. Ann Clin Biochem 2003; 40: 546-51
20. Haddad JG, Chyu KJ. Competitive protein-binding radioassay for 25-hydroxycholecalciferol. J Clin Endocrinol Metab 1971; 33: 992-5
21. 3 in human plasma by high-performance liquid chromatography. Clin Chem 1978; 24: 287-98
22. McKenna MJ, Freaney R. Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D. Osteoporosis Int 1998; 8(Suppl 2): S3-6
23. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998; 351: 805-6
24. Lips P, Duong T, Oleksik A, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 2001; 86: 1212-21
25. Glendenning P, Vasikaran SD. Vitamin D status and redefining serum PTH reference range in the elderly. J Clin Endocrinol Metab 2002; 87: 946-7
26. Hollis BW. Comparison of commercially available (125)I-based RIA methods for the determination of circulating 25-hydroxyvitamin D. Clin Chem 2000; 46: 1657-61
27. 3 or 1,25-dihydroxycholecalciferol. Lancet 1980; 2: 612-5
28. 3 in normal premenopausal women. Bone Miner 1986; 1: 407-13
29. 2. Am J Clin Nutr 1998; 68: 854-8
30. 3 supplement use on serum 25(OH)D concentration in elderly women in summer and winter. Calcified Tissue Int 2004; 74: 150-6. (Epub 2003 Dec 2005)
31. 3 in humans. J Clin Endocrinol Metab 2004; 89: 5387-91